

 **29 November 2024**

**SUMMARY OF PRODUCT CHARACTERISTICS**

**for**

**Mometasonfuroat "Aristo Pharma", nasal spray, suspension**

**0. D.SP.NO.**

33090

**1. NAME OF THE MEDICINAL PRODUCT**

Mometasonfuroat "Aristo Pharma"

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each actuation (0.1 ml) of the pump delivers a metered dose of mometasone furoate monohydrate equivalent to 50 micrograms mometasone furoate. The total weight of one actuation is 100 mg.

Excipient with known effect:

Each actuation (0.1 ml) contains 20 micrograms benzalkonium chloride per actuation. For the full list of excipients, see section 6.1.

**3. PHARMACEUTICAL FORM**

Nasal spray, suspension

White to off-white opaque suspension. pH: between 4.3 and 4.9

Osmolality: between 270 and 330 mOsm/Kg

**4. CLINICAL PARTICULARS**

**4.1 Therapeutic indications**

Mometasonfuroat "Aristo Pharma" is indicated for use in adults (from 18 years old) to treat the symptoms of seasonal allergic rhinitis, provided that the seasonal allergic rhinitis has initially been diagnosed by a physician.

**4.2 Posology and method of administration**

After initial priming of the Mometasonfuroat "Aristo Pharma" pump, each actuation delivers approximately 100 mg of mometasone furoate suspension, containing mometasone furoate monohydrate equivalent to 50 micrograms mometasone furoate.

Posology

*Adults (including older patients)*

The usual recommended dose is two actuations (50 micrograms/actuation) in each nostril once daily (total maximum daily dose 200 micrograms). Once symptoms are controlled, dose reduction to one actuation in each nostril (total dose 100 micrograms) may be effective for maintenance.

Mometason furoate demonstrated a clinically significant onset of action within 12 hours after the first dose in some patients with seasonal allergic rhinitis; however, full benefit of treatment may not be achieved in the first 48 hours. Therefore, the patient should continue regular use to achieve full therapeutic benefit.

Treatment with mometason furoate may need to be initiated some days before the expected start of the pollen season in patients who have a history of moderate to severe symptoms of seasonal allergic rhinitis.

In case no improvement is seen after 14 days, a physician should be contacted.

The product should not be taken for more than 3 months without medical supervision.

*Paediatric population*

Mometasonfuroat "Aristo Pharma" should not be used in children and adolescents below the age of 18.

Method of administration

Prior to administration of the first dose, shake container well and actuate the pump 10 times (until a uniform spray is obtained). If the pump is not used for 14 days or longer, reprime the pump with 2 actuations until a uniform spray is observed, before next use. Shake container well before each use. The bottle should be discarded after the labelled number of actuations or within 2 months of first use.

**4.3 Contraindications**

Hypersensitivity to the active substance, mometasone furoate or to any of the excipients listed in section 6.1. Mometasone furoate should not be used in the presence of untreated localised infection involving the nasal mucosa, such as herpes simplex.

Because of the inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal surgery or trauma should not use a nasal corticosteroid until healing has occurred.

**4.4 Special warnings and precautions for use**

Immunosuppression

Mometasone furoate should be used with caution, if at all, in patients with active or quiescent tuberculous infections of the respiratory tract, or in untreated fungal, bacterial or systemic viral infections.

Patients receiving corticosteroids who are potentially immunosuppressed should be warned of the risk of exposure to certain infections (e. g., chickenpox, measles) and of the importance of obtaining medical advice if such exposure occurs.

Local Nasal Effects

Following 12 months of treatment with mometasone furoate in a study of patients with perennial rhinitis, there was no evidence of atrophy of the nasal mucosa; also, mometasone furoate tended to reverse the nasal mucosa closer to a normal histologic phenotype. Nevertheless, patients using mometasone furoate over several months or longer should be examined periodically for possible changes in the nasal mucosa. If localised fungal infection of the nose or pharynx develops, discontinuation of Mometasonfuroat "Aristo Pharma" therapy or appropriate treatment may be required. Persistence of nasopharyngeal irritation may be an indication for discontinuing Mometasonfuroat "Aristo Pharma".

Mometasone furoate is not recommended in case of nasal septum perforation (see section 4.8).

In clinical studies, epistaxis occurred at a higher incidence compared with placebo. Epistaxis was generally self-limiting and mild in severity (see section 4.8).

Systemic Effects of Corticosteroids

Systemic effects of nasal corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations. Potential systemic effects may include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). Following the use of intranasal corticosteroids, instances of increased intraocular pressure have been reported (see section 4.8).

Patients who are transferred from long-term administration of systemically active corticosteroids to mometasone furoate require careful attention. Systemic corticosteroid withdrawal in such patients may result in adrenal insufficiency for a number of months until recovery of Hypothalamus-Pituitary-Adrenal (HPA) axis function. If these patients exhibit signs and symptoms of adrenal insufficiency or symptoms of withdrawal (e. g. joint and/or muscular pain, lassitude and depression initially), despite relief from nasal symptoms, systemic corticosteroid administration should be resumed and other modes of therapy and appropriate measures instituted. Such transfer may also unmask pre-existing allergic conditions, such as allergic conjunctivitis and eczema, previously suppressed by systemic corticosteroid therapy.

Treatment with higher than recommended doses may result in clinically significant adrenal suppression. If there is evidence for higher than recommended doses being used, then additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.

Non-nasal Symptoms

Although mometasone furoate will control the nasal symptoms in most patients, the

concommitant use of appropriate additional therapy may provide additional relief of other symptoms, particularly ocular symptoms.

Visual disturbance

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

Mometasonfuroat "Aristo Pharma" contains benzalkonium chloride

Benzalkonium chloride may cause irritation or swelling inside the nose, especially if used for a long time.

Mometasonfuroat "Aristo Pharma" contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per actuation, that is to say essentially 'sodium-free'.

**4.5 Interaction with other medicinal products and other forms of interaction**

(See section 4.4 “Systemic Effects of Corticosteroids”)

A clinical interaction study was conducted with loratadine. No interactions were observed.

Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.

**4.6 Fertility, pregnancy and lactation**

Pregnancy

There are no or limited amount of data from the use of mometasone furoate in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). As with other nasal corticosteroid preparations, Mometasonfuroat "Aristo Pharma" should not be used in pregnancy unless the potential benefit to the mother justifies any potential risk to the mother, fetus or infant. Infants born to mothers who received corticosteroids during pregnancy should be observed carefully for hypoadrenalism.

Breast-feeding

It is unknown whether mometasone furoate is excreted in human milk. As with other nasal corticosteroid preparations, a decision must be made to discontinue breast-feeding or to discontinue/abstain from mometasone furoate therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Fertility

There are no clinical data concerning the effect of mometasone furoate on fertility. Animal studies have shown reproductive toxicity, but no effects on fertility (see section 5.3).

**4.7 Effects on ability to drive and use machines**

No traffic warning.

Not known.

**4.8 Undesirable effects**

Summary of the safety profile

Epistaxis was generally self-limiting and mild in severity, and occurred at a higher incidence compared to placebo (5%), but at a comparable or lower incidence when compared to the active control nasal corticosteroids studied (up to 15%) as reported in clinical studies for allergic rhinitis. The incidence of all other adverse events was comparable with that of placebo. In patients treated for nasal polyposis, the overall incidence of adverse events was similar to that observed for patients with allergic rhinitis.

Systemic effects of nasal corticosteroids may occur, particularly when prescribed at high doses for prolonged periods.

Tabulated list of adverse reactions

Treatment-related adverse reactions (≥ 1%) reported in clinical trials in patients with allergic rhinitis or nasal polyposis and post-marketing regardless of indication are presented in Table 1. Adverse reactions are listed according to MedDRA primary system organ class. Within each system organ class, adverse reactions are ranked by frequency. Frequencies were defined as follows: Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100). The frequency of post-marketing adverse events are considered as “not known (cannot be estimated from the available data)”.

|  |
| --- |
| **Table 1: Treatment-related adverse reactions reported by system organ class and frequency** |
|  | Very common | Common | Not known |
| Infections and infestations |  | Pharyngitis, upper respiratory tract infection\*\* |  |
| Immune system disorders |  |  | Hypersensitivity including anaphylactic reactions, angioedema, bronchospasm, dyspnoea |
| Nervous system disorders |  | Headache |  |
| Eye disorders |  |  | Glaucoma, intraocular pressure increased, cataracts, vision, blurred (see also section 4.4) |
| Respiratory, thoracic and mediastinal disorders | Epistaxis\* | Epistaxis, nasal burning, nasal irritation, nasal ulceration | Nasal septum perforation |
| Gastrointestinal disorders |  | Throat irritation\* | Disturbances of taste and smell |

\* recorded for twice daily dosing for nasal polyposis

\*\* recorded at uncommon frequency for twice daily dosing for nasal polyposis

Paediatric population

In the paediatric population, the incidence of recorded adverse events in clinical studies, e. g. epistaxis (6%), headache (3%), nasal irritation (2%) and sneezing (2%) was comparable to placebo.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Lægemiddelstyrelsen

Axel Heides Gade 1

DK-2300 København S

Website: www.meldenbivirkning.dk

**4.9 Overdose**

Symptoms

Inhalation or oral administration of excessive doses of corticosteroids may lead to suppression of HPA axis function.

Management

Because the systemic bioavailability of Mometasonfuroat "Aristo Pharma" is < 1%, overdose is unlikely to require any therapy other than observation, followed by initiation of the appropriate prescribed dosage.

**4.10 Legal status**

Pack sizes ≤60 doses: HA18

Pack sizes >60 doses: B

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Decongestants and Other Nasal Preparations for Topical Use-Corticosteroids, ATC code: R01AD09

Mechanism of action

Mometasone furoate is a topical glucocorticosteroid with local anti-inflammatory properties at doses that are not systemically active.

It is likely that much of the mechanism for the anti-allergic and anti-inflammatory effects of mometasone furoate lies in its ability to inhibit the release of mediators of allergic reactions. Mometasone furoate significantly inhibits the release of leukotrienes from leucocytes of allergic patients. In cell culture, mometasone furoate demonstrated high potency in inhibition of synthesis and release of IL-1, IL-5, IL-6 and TNFα; it is also a potent inhibitor of leukotriene production. In addition, it is an extremely potent inhibitor of the production of the Th2 cytokines, IL-4 and IL-5, from human CD4+ T-cells.

Pharmacodynamic effects

In studies utilising nasal antigen challenge, mometasone furoate has shown anti-inflammatory activity in both the early- and late-phase allergic responses. This has been demonstrated by decreases (vs. placebo) in histamine and eosinophil activity and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins.

In 28% of the patients with seasonal allergic rhinitis, mometasone furoate nasal spray demonstrated a clinically significant onset of action within 12 hours after the first dose. The median (50%) onset time of relief was 35.9 hours.

Paediatric population

In a placebo-controlled clinical trial in which paediatric patients (n = 49/group) were administered mometasone furoate nasal spray 100 micrograms daily for one year, no reduction in growth velocity was observed.

There are limited data available on the safety and efficacy of mometasone furoate nasal spray in the paediatric population aged 3 to 5 years, and an appropriate dosage range cannot be established. In a study involving 48 children aged 3 to 5 years treated with intranasal mometasone furoate 50, 100 or 200 micrograms/day for 14 days, there was no significant differences from placebo in the mean change in plasma cortisol level in response to the tetracosactrin stimulation test.

**5.2 Pharmacokinetic properties**

Absorption

Mometasone furoate, administered as an aqueous nasal spray, has a systemic bioavailability of < 1% in plasma, using a sensitive assay with a lower quantitation limit of 0.25 pg/ml.

Distribution

Not applicable as mometasone is poorly absorbed via the nasal route.

Biotransformation

The small amount that may be swallowed and absorbed undergoes extensive first-pass hepatic metabolism.

Elimination

Absorbed mometasone furoate is extensively metabolised and the metabolites are excreted in urine and bile.

**5.3 Preclinical safety data**

No toxicological effects unique to mometasone furoate exposure have been demonstrated. All observed effects are typical of this class of compound and are related to exaggerated pharmacological effects of glucocorticoids.

Preclinical studies demonstrated that mometasone furoate is devoid of androgenic, antiandrogenic, estrogenic or antiestrogenic activity but, like other glucocorticoids, it exhibits some antiuterotrophic activity and delays vaginal opening in animal models at high oral doses of 56 mg/kg/day and 280 mg/kg/day.

Like other glucocorticoids, mometasone furoate showed a clastogenic potential *in vitro* at high concentrations. However, no mutagenic effects can be expected at therapeutically relevant doses.

In studies of reproductive function, subcutaneous mometasone furoate, at 15 micrograms/kg prolonged gestation and prolonged and difficult labour occurred with a reduction in offspring survival and body weight or body weight gain. There was no effect on fertility.

Like other glucocorticoids, mometasone furoate is a teratogen in rodents and rabbits. Effects noted were umbilical hernia in rats, cleft palate in mice and gallbladder agenesis, umbilical hernia, and flexed front paws in rabbits. There were also reductions in maternal body weight gains, effects on fetal growth (lower fetal body weight and/or delayed ossification) in rats, rabbits and mice, and reduced offspring survival in mice.

The carcinogenicity potential of inhaled mometasone furoate (aerosol with CFC propellant and surfactant) at concentrations of 0.25 to 2.0 micrograms/l was investigated in 24-month studies in mice and rats. Typical glucocorticoid-related effects, including several non-neoplastic lesions, were observed. No statistically significant dose-response relationship was detected for any of the tumour types.

Enviromental risk assessment studies have shown that mometasone may pose a risk to surface water (see section 6.6).

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Microcrystalline cellulose

Carmellose sodium

Glycerol

Sodium citrate dihydrate (for pH adjustment)

Citric acid monohydrate (for pH adjustment)

Polysorbate 80

Benzalkonium chloride

Water for Injection

**6.2 Incompatibilities**

Not applicable.

**6.3 Shelf life**

2 years

Use within 8 weeks of first use.

**6.4 Special precautions for storage**

Do not freeze.

**6.5 Nature and contents of container**

Mometasonfuroat "Aristo Pharma" is contained in a white, high density polyethylene bottle, that contains 10 g (60 actuations) or 18 g (140 actuations) of suspension, supplied with a metered-dose, manual polypropylene spray pump and actuator.

Pack sizes: 10 g, 1 bottle containing 60 actuations

18 g, 1 bottle containing 140 actuations

Not all pack sizes may be marketed

**6.6 Special precautions for disposal and other handling**

This medicinal product may pose a risk to the environment (see section 5.3).

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Aristo Pharma GmbH

Wallenroder Str. 8-10

13435 Berlin

Germany

**8. MARKETING AUTHORISATION NUMBER(S)**

68165

**9. DATE OF FIRST AUTHORISATION**

29 November 2024

**10. DATE OF REVISION OF THE TEXT**

-